Australia's largest stock trading and investment forum Australia's #1 stock forum

GMV

0.00%

3.9¢ g medical innovations holdings limited

Ann: ASX Confirms G Medical Delisting, page-328

First 328 Last

Share
Profile

Follow
hkhf

2,175 Posts.

938

24/09/20

01:10

Post #: 47583763
Share

Originally posted by hkhf: ↑

The following is part of Section 2.2 of the Anns -"NOTICE OFEXTRAORDINARY GENERAL MEETING" (dated 21/08/2020):

2.2 Key reasons for seeking approval for Removal and related advantages
(a) Intention to list on NASDAQ
(i) In October 2018, the Company announced its intention to undertake a public
offering in the United States via the issue of Shares (NASDAQ Shares) to raise
up to A$34,984,607 (before costs) (US Public Offer) in connection with its
proposed listing on NASDAQ. The NASDAQ Shares were to be issued as
American Depositary Shares (ADS) to participants in the US Public Offer.
(ii) The Company had determined that the issue of the NASDAQ Shares would
exceed its 15% placement capacity and, in April 2019, the Company obtained
Shareholder approval pursuant to Listing Rule 7.1 to issue the NASDAQ Shares
at a price of not less than A$0.20 (Floor Price).
...
...

So in 2018 the company initially intended to raise A$35m in US Public Offer, and later gave up due to then company's situation as well as the capacity restrictions (and its asx sp connection) instead went with OTC listing (GMMVF) in the end without raising expected money. Two years later now asx delisting is almost certain and the company seems making good progress in US market. All become interesting/achievable (in ipo) again plus it's single listing this time! As August patient numbers/revenues are not published/confirmed yet, my following prices/shares estimate is purely speculating (exercise) as well:

After 2 years, assume GMV now needs to raise more than A$35m, say A$40m this time, approximately ~US$30m. As many already pointed out that the minimum Nasdaq listing SP is US$4.00. So GMV US IPO will have to issue at least 7.5m new shares. Current GMV ASX total SOI is circa 838.8m, assume a 100:1 consolidation ratio, it will become circa 8.4m shares.
So if:
IPO price IPO shares Existing/old shares(after 100:1 consolidation) Total SOI New Mktcap
US$4.00 7.5m 8.4m 15.9m US$63.6m(A$87m)
US$6.00 5m 8.4m 13.4m US$80.4m(A$110m)
US$10.00 3m 8.4m 11.4m US$114m(A$156m)
US$15.00 2m 8.4m 10.4m US$156m(A$214m)
......
Using AUD/USD= 0.73 exchange rate:
US$4.00 IPO is equivalent to the current sp A$0.055;
US$6.00 IPO is equivalent to the current sp A$0.082;
US$10.00 IPO is equivalent to the current sp A$0.137;
US$15.00 IPO is equivalent to the current sp A$0.205;
......

All are speculative based on the assumption of US$30m IPO plus a 100:1 consolidation on ASX total current SOI (different assumptions can easily change the sp projection). Also depending on US macro environment at the time of IPO and more critically the confirmed patient numbers and revenues by then!
(i personally think Nasdaq listing approval should have no problem, it's the timing of IPO in US is tricky. Anyway not long now!)

Expand

Sorry HC removed the spaces in the table, should be like below:

GMV Price at posting: 3.9¢ Sentiment: None Disclosure: Held
13 Upvote

1 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 28 more messages in this thread...

First 328 Last

Add GMV (ASX) to my watchlist

Ann: ASX Confirms G Medical Delisting, page-328

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News